Up-regulation of DNAM-1 and NKp30, associated with improvement of NK cells activation after long-term culture of mononuclear cells from patients with ovarian neoplasia

Human Immunology

Volumn 75, Issue 8, 2014, Pages 777-784

  da Silva, Rodrigo Fernandes ^a   Petta, Carlos Alberto ^a   Derchain, Sophie Françoise ^a   Alici, Evren ^b   Guimarães, Fernando ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

CD107a; Degranulation; NCRs (natural cytotoxic receptors); NK like T lymphocytes; Regulatory T cells

Indexed keywords

CD56 ANTIGEN; DNAX ACCESSORY MOLECULE 1; INTERLEUKIN 2; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 2; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 3; PROTEIN; UNCLASSIFIED DRUG; CD226 ANTIGEN; NCR3 PROTEIN, HUMAN; T LYMPHOCYTE ANTIGEN;

ADNEXA DISEASE; ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER GRADING; CELL SUSPENSION; CLINICAL ARTICLE; CONTROLLED STUDY; DEGRANULATION; EFFECTOR CELL; FEMALE; HUMAN; HUMAN CELL; INFORMED CONSENT; LEUKOCYTE CULTURE; LONG TERM CULTURE; LYMPHOCYTE FUNCTION; NATURAL KILLER T CELL; OVARY CANCER; OVARY TUMOR; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; SHORT TERM CULTURE; T LYMPHOCYTE ACTIVATION; CANCER STAGING; CASE CONTROL STUDY; COLLOID CARCINOMA; CYSTADENOCARCINOMA; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MIDDLE AGED; NATURAL KILLER CELL; OVARY; PATHOLOGY; PRIMARY CELL CULTURE; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; VERY ELDERLY;

ADENOCARCINOMA, MUCINOUS; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; CASE-CONTROL STUDIES; CYSTADENOCARCINOMA, SEROUS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-2; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; LYSOSOMAL-ASSOCIATED MEMBRANE PROTEIN 1; MIDDLE AGED; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 3; NEOPLASM STAGING; OVARIAN NEOPLASMS; OVARY; PRIMARY CELL CULTURE; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, REGULATORY;

EID: 84905122718     PISSN: 01988859     EISSN: 18791166     Source Type: Journal    
DOI: 10.1016/j.humimm.2014.05.010     Document Type: Article

References (40)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012, 62:10-29.
2. Naora H., Montell D.J. Ovarian cancer metastasis: integrating insights from disparate model organisms. Nat Rev Cancer 2005, 5:355-366.
3. Lotzova E., Savary C.A., Freedman R.S., Edwards C.L., Wharton J.T. Recombinant IL-2-activated NK cells mediate LAK activity against ovarian cancer. Int J Cancer 1988, 42:225-231.
4. Roszkowski P.I., Hyc A., Malejczyk J. Natural killer cell activity in patients with ovarian tumors and uterine myomas. Eur J Gynaecol Oncol 1993, 14:114-117.
5. Stremmel C., Exley M., Balk S., Honenberger W., Kuchroo V.K. Characterization of the phenotype and function of CD8+, α/β NKT cells from tumor-bearing mice that show a natural killer cell activity and lyse multiple tumor targets. Eur J Immunol 2001, 31:2818-2828.
6. Gritzapis A.D., Dimitroulopoulos D., Paraskevas E., Baxevanis C.N., Papamichail M. Large-scale expansion of CD3+CD56+ lymphocytes capable of lysing autologous tumor cells with cytokine-rich supernatants. Cancer Immunol Immunother 2002, 51:440-448.
7. Lamkin D.M., Lutgendorf S.K., Minh Dao S.M., Maiseri H., DeGeest K., Sood A.K., et al. Positive psychosocial factors and NKT cells in ovarian cancer patients. Brain Behav Immun 2008, 22:65-73.
8. Carlsten M., Malmberg K.J., Ljunggren H.G. Natural killer cell-mediated lysis of freshly isolated human tumor cells. Int J Cancer 2009, 124:757-762.
9. Kiessling R., Klein E., Pross H., Wigzell H. "Natural" killer cells in the mouse. II. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Characteristics of the killer cell. Eur J Immunol 1975, 5:117-121.
10. Herberman R.B., Nunn M.E., Holden H.T., Lavrin D.H. Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. II. Characterization of effector cells. Int J Cancer 1975, 16:230-239.
11. Moretta L., Moretta A. Unravelling natural killer cell function: triggering and inhibitory human NK receptors. EMBO J 2004, 23:255-259.
12. Long E.O. Negative signaling by inhibitory receptors: the NK cell paradigm. Immunol Rev 2008, 224:70-84.
13. Sivori S., Pende D., Bottino C., Marcenaro E., Pessino A., Biassoni R., et al. NKp46 is the major triggering receptor involved in the natural cytotoxicity of fresh or cultured human NK cells. Correlation between surface density of NKp46 and natural cytotoxicity against autologous, allogeneic or xenogeneic target cells. Eur J Immunol 1999, 29:1656-1666.
14. Coudert J.D., Zimmer J., Tomasello E., Cebecauer M., Colonna M., Vivier E., et al. Altered NKG2D function in NK cells induced by chronic exposure to NKG2D ligand-expressing tumor cells. Blood 2005, 106:1711-1717.
15. El-Sherbiny Y.M., Meade J.L., Holmes T.D., McGonagle D., Mackie S.L., Morgan A.W., et al. The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells. Cancer Res 2007, 67:8444-8449.
16. Kaifu T., Escaliere B., Gastinel L.N., Vivier E., Baratin M. B7-H6/NKp30 interaction: a mechanism of alerting NK cells against tumors. Cell Mol Life Sci 2011, 68:3531-3539.
17. Bryceson Y.T., March M.E., Ljunggren H.G., Long E.O. Activation, coactivation, and costimulation of resting human natural killer cells. Immunol Rev 2006, 214:73-91.
18. Malmberg K.J., Bryceson Y.T., Carlsten M., Andersson S., Björklund A., Björkström N.K., et al. NK cell-mediated targeting of human cancer and possibilities for new means of immunotherapy. Cancer Immunol Immunother 2008, 57:1541-1552.
19. Alici E., Sutlu T., Björkstrand B., Gilljam M., Stellan B., Nahi H., et al. Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components. Blood 2008, 111:3155-3162.
20. Schmidt R.E., Murray C., Daley J.F., Schlossman S.F., Ritz J. A subset of natural killer cells in peripheral blood displays a mature T cell phenotype. J Exp Med 1986, 164:351-356.
21. Ortaldo J.R., Winkler-Pickett R.T., Yagita H., Young H.A. Comparative studies of CD3+ and CD3+CD56+ cells. Examination of morphology, functions, Tcell receptor rearrangement, and pore-forming protein expression. Cell Immunol 1991, 136:486.
22. Pievani A., Borleri G., Pende D., Moretta L., Rambaldi A., Golay J., et al. Dual-functional capability of CD3+CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity. Blood 2011, 118:3301-3310.
23. Alves P.C.M., Andrade L.A.L.A., Petta C.A., Lorand́Metze I., Derchain S.F.M., Guimarães F. Ex vivo expansion of CD56 NK and NKT-like lymphocytes from peripheral blood mononuclear cells of patients with ovarian neoplasia. Scand J Immunol 2011, 74:244-252.
24. Giroux M., Denis F. CD1d-unrestricted human NKT cells release chemokines upon Fas engagement. Blood 2005, 105:703-710.
25. Peralbo E., Alonso C., Solana R. Invariant NKT and NKT-like lymphocytes: two different T cell subsets that are differentially affected by ageing. Exp Gerontol 2007, 42:703-708.
26. Malmberg K.J. Effective immunotherapy against cancer: a question of overcoming immune suppression and immune escape?. Cancer Immunol Immunother 2004, 53:879-892.
27. Yigit R., Massuger L.F.A.G., Figdor C.G., Torensma R. Ovarian cancer creates a suppressive microenvironment to escape immune elimination. Gynecol Oncol 2010, 117:366-372.
28. Lai P., Rabinowich H., Crowley-Nowick P.A., Bell M.C., Montovani G., Whiteside T.L. Alterations in expression and function of signal-transducing proteins in tumor-associated T and natural killer cells in patients with ovarian carcinoma I. Clin Cancer Res 1996, 2:161-173.
29. Lutgendorf S.K., Sood A.K., Anderson B., McGinn S., Maiseri H., Dao M., et al. Social support, psychological distress, and natural killer cell activity in ovarian cancer. J Clin Oncol 2005, 23:7105-7113.
30. Carlsten M., Björkström N.K., Norell H., Bryceson Y., van Hall T., Baumann B.C., et al. DNAX accessory molecule-1 mediated recognition of freshly isolated ovarian carcinoma by resting natural killer cells. Cancer Res 2007, 67:1317-1325.
31. Carlsten M., Norell H., Bryceson Y.T., Poschke I., Schedvins K., Ljunggren H.G., et al. Primary human tumor cells expressing CD155 impair tumor targeting by down-regulating DNAM-1 on NK cells. J Immunol 2009, 183:4921-4930.
32. Carlens S., Gilljam M., Chambers B.J., Aschan J., Guven H., Ljunggren H.G., et al. A new method for in vitro expansion of cytotoxic human CD3-CD56+ natural killer cells. Hum Immunol 2001, 62:1092-1098.
33. Bryceson YT, Fauriat C, Nunes JM, Wood SM, Björkström NK, Long EO, Ljunggren HG. Functional Analysis of Human NK Cells by Flow Cytometry. Chapter 23. K.S. Campbell (Ed.), Natural Killer Cell Protocols, Meth Mol Biol 612, 2010, doi: 10.1007/978-1-60761-362-6 23.
34. Geller M.A., Cooley S., Judson P.L., Ghebre R., Carson L.F., Argenta P.A., et al. A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy 2011, 13:98-107.
35. Woo E.Y., Chu C.S., Goletz T.J., et al. Regulatory CD4+CD25+ T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 2001, 61:4766-4772.
36. Curiel T.J., Coukos G., Zou L., Alvarez X., Cheng P., Mottram P., et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004, 10:942-949.
37. Wolf D., Wolf A.M., Rumpold H., et al. The expression of regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res 2005, 11:8326-8331.
38. Bamias A., Koutsoukou V., Terpos E., Tsiatas M.L., Liakos C., Tsitsilonis O., et al. Correlation of NK T-like CD3+CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF and TNFα in ascites from advanced ovarian cancer: association with platinum resistance and prognosis in patients receiving first-line, platinum based chemotherapy. Gynecol Oncol 2008, 108:421-427.
39. Fiegler N., Textor Sonja, Arnold A., Rolle A., Oehme I., Breuhahn K., Moldenhauer G., Witzens-Harig M., Cerwenka A. Downregulation of the activating NKp30 ligand B7-H6 by HDAC inhibitors impairs tumor cell recognition by NK cells. Blood 2013, 122:684-693.
40. Sutlu T., Stellan B., Gilljam M., Quezada H.C., Nahi H., Gahrton G., et al. Clinical-grade, large-scale, feeder-free expansion of highly active human natural killer cells for adoptive immunotherapy using an automated bioreactor. Cytotherapy 2010, 12:1044-1055.